|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||85.40 - 89.37|
|52 Week Range||72.05 - 158.80|
|Beta (3Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 22, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||187.86|
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Valaris Plc (VAL), Sarepta Therapeutics, Inc. (SRPT), Canada Goose Holdings, Inc. (GOOS), and Meredith Corporation (MDP). On July 31, 2019, Valaris issued a press release announcing its second quarter 2019 financial results—its first earnings report post-merger reflecting the results of the combined company—which missed market expectations (the “2Q 2019 Press Release”). Upon issuance of the 2Q 2019 Press Release, Seeking Alpha published an article on August 2, 2019, entitled “Valaris PLC - Off To A Bad Start” (the “Seeking Alpha Article”), noting that Valaris’s results “shock[ed] investors with massive cash usage [and] .
NEW YORK, Oct. 15, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).
The major biotech exchange-traded funds are failing to keep up with the market this year, despite a strong showing in the first few months of the year. Evercore ISI analysts Ravi Mehrotra and Josh Schimmer suggest that gene therapy might be the reason. The analysts wrote in a Sunday note that they had constructed a proprietary index of gene therapy companies, and found the companies had “massively” underperformed in the second half of the year.
Is Sarepta Therapeutics Inc (NASDAQ:SRPT) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (SRPT) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-08122, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise, acquired publicly traded Sarepta securities between September 6, 2017 and August 19, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
NEW YORK, NY / ACCESSWIRE / October 9, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...
NEW YORK, Oct. 09, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics,.
NEW YORK, Oct. 08, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
New York, New York--(Newsfile Corp. - October 8, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) ("Sarepta" or the "Company") of the October 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoCannot view this image? Visit:https://orders.newsfilecorp.com/files/6455/48554_e979f4b5246ba979_logo.jpgIf you invested in Sarepta stock or options between ...
NEW YORK, NY / ACCESSWIRE / October 7, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
NEW YORK, NY / ACCESSWIRE / October 7, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
Early Friday, Sarepta Therapeutics unveiled promising results for a gene therapy known as SRP-9003 in three patients with a form of muscular dystrophy — prodding Sarepta stock to pop.
(Bloomberg) -- Sarepta Therapeutics Inc.’s bulls may get some validation after the company’s experimental gene therapy for a rare type of muscular dystrophy improved physical fitness in a trio of patients.Updated data for the experimental compound showed patients with an inherited form of Limb-girdle muscular dystrophy reaped functional benefits in several areas after receiving SRP-9003, with a pair of teenagers posting gains in their ability to move when they typically would have experienced declines. Analysts had stressed that promising results could help the company shake-off a recent rout that wiped out $6 billion in market value as questions about the company’s drug pipeline mounted.The results for the three patients showed a 1.3 second to 10.9 second improvement in the time it took to run 100 meters and a 0.1 second to 0.9 second benefit in their ability to climb four stairs. That contrasts with Evercore ISI’s assessment that “any improvement or even stabilization on the various functional endpoints could be interpreted as positive drug effect by the Street.”Shares of the Cambridge, Massachusetts-based drugmaker rose as much as 9.7% Friday, on pace to extend their longest winning streak since February. The rally comes after the stock closed near a 17-month low on Sept. 26 as the broader market churned.“On every single functional endpoint, every patient is improving,” Chief Executive Doug Ingram said, expressing confidence in the program. Even a stabilization in measures such as the North Star Assessment for Dysferlinopathy (NSAD) would have been a great indicator, Ingram continued, though the number of patients treated is small and the results are early.Production of an enzyme that the muscle releases when it’s being damaged, known as CK, fell an average of 82% at nine months, slipping slightly from the 90% reduction seen previously. The company executives attributed the incremental decline to increased patient activity and said they remained focused on the broader benefit as another promising sign. The initial results, shown in February, fueled an 8.3% rise to a five-month high.“The take home message is that on every single measure, patients improved across the board,” Louise Rodino-Klapac, Sarepta senior vice president of gene therapy, said by phone.The patient benefit looked “highly impressive” to RBC analyst Brian Abrahams, who wrote in a note there was “little to nitpick” from the data. Friday’s news is “an important step” toward starting to turnaround sentiment for the company and Abrahams advised investors buy into the stock’s strength.The company plans to infuse additional patients with a higher dose of SRP-9003 so it can compare the benefits before selecting which to strength to take into a larger study.“We want to dose the patients as soon as possible,” Ingram said. “Our goal is to try and get them dosed this year if at all possible.”Skeptics of Sarepta’s Limb-girdle program have highlighted that the natural history of the disease isn’t well known, limiting the ability to compare benefits using data from just three patients. There have also been concerns that the two 13-year-old patients are likely in the declining phase of muscle function, while the four-year-old is still growing. That could make the improvements even more difficult to interpret.No new safety signals were seen in the updated data, supporting plans to test a higher dose of the gene therapy. It’s worth noting that there are no current treatment options for the rare, progressive disease, which leads to weakness and atrophy of the muscles supporting the hips and shoulders.Despite the promising results, investors are likely to remain laser-focused on mid-stage data from the company’s Duchenne muscular dystrophy gene therapy, with data expected next year. In addition to patients with Limb-girdle disease-2E, Sarepta has four other programs for the broader limb-girdle patient population.(Updates with share movement in fourth paragraph, RBC commentary in ninth)To contact the reporter on this story: Bailey Lipschultz in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Michelle Fay Cortez, Cristin FlanaganFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
NEW YORK, Oct. 04, 2019 -- NEW YORK, October 4, 2019 – The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced the nine-month functional results from three Limb-girdle muscular dystrophy Type 2E (LGMD2E) clinical trial participants who received SRP-9003. SRP-9003 is an investigational gene therapy intended to transduce skeletal and cardiac muscle with a gene that codes for the full-length, native beta-sarcoglycan protein, the lack of which is the sole cause of LGMD2E. “We have now observed consistent functional improvements, in addition to high levels of expression of the missing protein of interest and strong results in related biomarkers, in both of our first cohorts for Duchenne muscular dystrophy (SRP-9001) and LGMD2E (SRP-9003).